← brief for 2026-09-03 · People & money

Cardiovascular–Kidney–Metabolic Syndrome Pharmacoeconomics, and the Journey to India-Specific Evidence

Key takeaways

This is a commentary on the cost of treating the linked cluster of heart, kidney and metabolic disease, and it argues India needs its own cost data rather than borrowing numbers from other countries. It is an opinion and policy piece. There are no patient results here.

Who did this work

Muhammad Aaqib Shamim (All India Institute of Medical Sciences Jodhpur) · R. Shukla (All India Institute of Medical Sciences Jodhpur) · Manish Chaturvedy (All India Institute of Medical Sciences Jodhpur) · Rajesh Jhorawat (All India Institute of Medical Sciences Jodhpur) · Kuldeep Singh (All India Institute of Medical Sciences Jodhpur) · Shoban Babu Varthya (All India Institute of Medical Sciences Jodhpur) · Surjit Singh (All India Institute of Medical Sciences Jodhpur) · Pradeep Dwivedi (All India Institute of Medical Sciences Jodhpur)

Source

Paper · OpenAlex, CKD works · 2026-09-01
https://doi.org/10.1016/j.glmedi.2026.100250